

Borreliose Impfung Lyme Vaccination

Steere AC, Sikand VK, Meurice F, et al. (1998) Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. *N Engl J Med* 339, 209-215.

<http://www.nejm.org/doi/full/10.1056/NEJM199807233390401>

Noble HB. (2000) 3 Suits Say Lyme Vaccine Caused Severe Arthritis. *New York Times*. June 13.

<http://www.nytimes.com/2000/06/13/science/3-suits-say-lyme-vaccine-caused-severe-arthritis.html> Accessed 1/16/2014.

Molloy PJ, Berardi VP, Persing DH, Sigal LH. (2000) Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A Lyme disease vaccination. *Clin Infect Dis* 31, 42–47.

Fawcett PT, Rose CD, Budd SM, Gibney KM. (2001) Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis. *Clin Diagn Lab Immunol* 8, 79–84.

Smith P. (2001) Remarks to Vaccines and Related Biological Products Advisory Committee, Bethesda, MD.

http://www.lymediseaseassociation.org/index.php?option=com_content&view=article&id=262

GlaxoSmithKline. (2001) Package Insert – LYMERix Lyme Disease Vaccine (Recombinant OspA).

http://us.gsk.com/products/assets/us_lymerix.pdf (131 KB). Accessed 1/16/2014.

Smith P, Gaito A, Marks DH. (2002) Transcript of FDA Lymerix meeting, Bethesda, MD.

<http://www.lymediseaseassociation.org/index.php/food-a-drug-administration-fda/532-lymerix-meeting>

Lathrop SL, Ball R, Haber P et al. (2002) Adverse event reports following vaccination for Lyme disease: December 1998–July 2000. *Vaccine*. 20, 1603-1608.

<http://www.sciencedirect.com/science/article/pii/S0264410X0100500X> Accessed 1/16/2014

Willett TA, Meyer AL, Brown EL, et al. (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. *Proc Natl Acad Sci U S A* 101, 1303-1308.

Littman MP, Goldstein RE, Labato MA, et al. (2006) ACVIM Small Animal Consensus Statement on Lyme Disease in Dogs: Diagnosis, Treatment, and Prevention. *J Vet Intern Med* 20, 422-434.

Editorial (2006) When a vaccine is safe. *Nature*. 439, 509.

<http://www.nature.com/nature/journal/v439/n7076/full/439509a.html>

McSweegan (2007) The Lyme vaccine : a cautionary tale. *Epidemiol. Infect.* 135, 9-10

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870557/>

[Nigrovic LE](#), [Thompson KM](#) (2007) The Lyme vaccine: a cautionary tale. *Epidemiol Infect.* 135(1), 1-8.

<http://www.ncbi.nlm.nih.gov/pubmed/16893489>

Stricker RB. (2008) Lymerix risks revisited. *Microbe* 3, 1–2.

Souayah N, Ajroud-Driss S, Sander HW, Brannagan TH, Hays AP, Chin RL. (2009) Small fiber neuropathy following vaccination for rabies, varicella or Lyme disease. *Vaccine* 27, 7322–25.

Nardelli DT, Munson EL, Callister SM, Schell RF. (2009) Human Lyme Disease Vaccines: Past and Future Concerns. *Future Microbiology*. 4(4), 457-469.

Seemanapalli SV, Xu Q, McShan K, Liang FT (2010) Outer Surface Protein C Is a Dissemination-Facilitating Factor of *Borrelia burgdorferi* during. *Mammalian Infection*. *PLoS ONE* 5(12), e15830. doi:10.1371/journal.pone.0015830

Marks DH. (2011) Neurological complications of vaccination with outer surface protein A (OspA). *Int J Risk Saf Med* **23**, 89–96.

Lively I, O'Rourke MO, Traweger A et al. (2011) A New Approach to a Lyme Disease Vaccine. *Clinical Infectious Diseases* 52(S3), 266–270

Kumar M, et al. (2011) *Borrelia burgdorferi* BBA52 is a potential target for transmission blocking Lyme disease vaccine. *Vaccine* doi:10.1016/j.vaccine.2011.09.035

Shen AK, Mead PS, Beard CB (2011) The Lyme Disease Vaccine—A Public Health Perspective. *Lyme Disease Vaccine and Public Health* 52(3), 247-252

Bhattacharya D, et al. (2011) Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. *Vaccine* doi:10.1016/j.vaccine.2011.07.100

Allen C, Steere AC, Elise E, Drouin EE, and Lisa J, Glickstein LJ (2011) Relationship between Immunity to *Borrelia burgdorferi* Outer-surface Protein A (OspA) and Lyme Arthritis. *Clinical Infectious Diseases* 52(S3), 259–S265

Steere AC, Drouin EE, Glickstein LJ, (2011) Relationship between Immunity to *Borrelia burgdorferi* Outer-surface Protein A (OspA) and Lyme Arthritis. *Clinical Infectious Diseases* 52(S3), 259-265. http://cid.oxfordjournals.org/content/52/suppl_3/s259.full.pdf+html

Poland GA. (2011) Vaccines against Lyme disease: What happened and what lessons can we learn? *Clin Infect Dis.* 52 (Suppl 3), s253-8. doi:10.1093/cid/ciq116. http://cid.oxfordjournals.org/content/52/suppl_3/s253.long

Krupka M, Masek J, Bartheldyova E et al. (2012) Enhancement of immune response towards non-lipidized *Borrelia burgdorferi* recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP, *Journal of Controlled Release*, doi:10.1016/j.jconrel.2012.02.017

Bensaci M, Bhattacharya D et al. (2012) Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of *Borrelia burgdorferi*. *Vaccine* 30, 6040–6046

Leventhal JS, Berger EM, Brauer JA et al. (2012) Hypersensitivity Reactions to Vaccine Constituents: A Case Series and Review of the Literature. *DERMATITIS*, 23(3), 102-109

Aronowitz RA (2012) The Rise and Fall of the Lyme Disease Vaccines: A Cautionary Tale for Risk Interventions in American Medicine and Public Health. *The Milbank Quarterly*, 90(2), 250–277 <http://www.ncbi.nlm.nih.gov/pubmed/22709388> http://www.aldf.com/pdf/Aronowitz_The_Rise_and_Fall_of_Lyme_Vaccines.pdf

de la Fuente J, Merino O. (2013) Vaccinomics, the new road to tick vaccines. *Vaccine*. <http://dx.doi.org/10.1016/j.vaccine.2013.10.049>

Wressnigg N, Pollabauer E-M, Aichinger G, et al. (2013) Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. *Lancet Infect Dis* 13, 680–89.

Lantos PM. (2013) Lyme disease vaccination: are we ready to try again? *Lancet Infect Dis* 13, 643–44. <http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970085-9/fulltext>

Plotkin SA (2013) Bring Back the Lyme Vaccine. <http://www.nytimes.com/2013/09/19/opinion/bring-back-the-lyme-vaccine.html>

Wressnigg N, Pöllabauer EM, Aichinger G (2013) **Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults:** a double-blind, randomised, dose-escalation phase 1/2 trial www.thelancet.com/infection Published online May 10, 2013

[http://dx.doi.org/10.1016/S1473-3099\(13\)70110-5](http://dx.doi.org/10.1016/S1473-3099(13)70110-5)

<http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970110-5/abstract>

„We investigated the safety and immunogenicity of adjuvanted and non-adjuvanted vaccines containing protective epitopes from *Borrelia* species outer surface protein A (OspA) serotypes in healthy adults.“

Phase 1/2 Lyme Vaccine Study <http://clinicaltrials.gov/show/NCT01504347> Accessed 1/16/2014.

Wressnigg N, Barrett PN, Pöllabauer E-M et al. (2014) **A Novel Multivalent OspA 1 Vaccine against Lyme Borreliosis is Safe and Immunogenic in an Adult Population Previously Infected with *Borrelia burgdorferi sensu lato***. CVI Accepts, published online ahead of print on 3 September 2014 Clin. Vaccine Immunol. doi:10.1128/CVI.00406-14

« We have developed a novel multivalent OspA vaccine, which comprises three recombinant OspA antigens, each containing protective epitopes from two different OspA serotypes i.e. OspA serotypes 1 and 2 (*B. burgdorferi* s.s. and *B. afzelii*); 5 and 3 (both *B. garinii*); and 6 and 4 (*B. garinii* and *B. bavariensis*) (22). The multivalent vaccine is designed to protect against all major disease-causing *Borrelia* species in the US (OspA-1) and Europe (OspA 1-6), and potentially globally“.

[Stricker RB](#), [Johnson L](#) (2014) **Lyme disease vaccination: safety first**. The Lancet Infectious Diseases, [14\(1\)](#), 12 doi:10.1016/S1473-3099(13)70319-0 [Cite or Link Using DOI Inclusively authors reply](#). http://download.thelancet.com/pdfs/journals/laninf/PIIS1473309913703190.pdf?id=jaaR4JzkdCyL_9u5IYAEu

Comstedt P, Hanner M, Schöler W et al. (2014) **Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis**. PLoSone. 9(11), e113294
<http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0113294&representation=PDF>
<http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0113294&representation=PDF>

[Comstedt P](#), [Hanner M](#), [Schöler W](#) et al. (2015) **Characterization and optimization of a novel vaccine for protection against Lyme borreliosis**. [Vaccine](#). pii: S0264-410X(15)01099-3. doi: 10.1016/j.vaccine.2015.07.095. <http://www.ncbi.nlm.nih.gov/pubmed/26277070>

Zhao H, Bao FF, Liu A (2017) **Safety, immunogenicity, and efficacy of *Borrelia burgdorferi* outer surface protein A (OspA) vaccine: A meta-analysis**. J Infect Dev Ctries 11(1), 1-9. doi:10.3855/jidc.7999 <https://www.ncbi.nlm.nih.gov/pubmed/11433064>

[Comstedt P](#), [Schöler W](#), [Meinke A](#), [Lundberg U](#) (2017) **The novel Lyme borreliosis vaccine VLA15 shows broad protection against *Borrelia* species expressing six different OspA serotypes**. [PLoS One](#). 12(9), e0184357. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581183/>

➔ The History of the Lyme Vaccines

<http://www.historyofvaccines.org/content/articles/history-lyme-disease-vaccine>

Impfstoffzusätze, Kontroversen und Miss-Verständnisse, Vaccine additives, controversies and misunderstandings

Sen S, Cloete Y, Hassan K, Buss P (2001) **Adverse events following vaccination in premature infants**, Acta Paediatrica, [Aug:90\(8\):916-20](#).

Bonhoeffer J, Siegrist C-A, Heath PT (2006) **Immunisation of premature infants**, Archives of Disease in Childhood, Nov; 91(11), 929–935. DOI: [10.1136/adc.2005.086306](https://doi.org/10.1136/adc.2005.086306)

DeMeo SD, Raman SR, Hornik ChP et al. (2015) **Adverse Events After Routine Immunization of Extremely Low Birth Weight Infants**, JAMA Pediatrics, 2015 Aug 1; 169(8), 740–745. DOI: [10.1001/jamapediatrics.2015.0418](https://doi.org/10.1001/jamapediatrics.2015.0418)

[Gherardi RK](#), [Eidi H](#), [Crépeaux G](#) et al. (2015) **Biopersistence and brain translocation of aluminum adjuvants of vaccines**. Front. Neurol, doi: 10.3389/fneur.2015.00004
<http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00004/full>

Gatti AM, Montanari S (2017) **New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination.** International Journal of Vaccines and Vaccination 4(1), 00072
http://www.whale.to/c/vaxcontaminants_IJVV-04-00072.pdf

Adams M (2017) **VACCINE RAGE explains why the world is going INSANE**
<https://vimeo.com/216200564>

Ortel Ch. (2017) **Truth About Vaccines.**
<https://sites.google.com/site/lymevaccine/truth-about-vaccines-series>

Mawson AR, Ray BD, Bhuiyan AR, Jacob B (2017) **Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12- year old U.S children,** Journal of Translational Science, DOI: [10.15761/JTS.1000186](https://doi.org/10.15761/JTS.1000186)

Jaxen J (2017) **Vaccinated Vs. Unvaccinated Pilot Study: Early Vaccination Sees Exponential Increase in Chronic Disorders.**
<http://www.greenmedinfo.com/blog/vaccinated-vs-unvaccinated-pilot-study-early-vaccination-sees-exponential-increas>

Vaccination - to reduce population! (Bill Gates admits)
<https://www.youtube.com/watch?v=pjj4lq-rsNg>

Bill Gates says Reduce Population 4 TIMES!!
<https://www.youtube.com/watch?v=8BobKXkrt8M>
<https://www.youtube.com/watch?v=8BobKXkrt8M#t=156.8733235>

R.E.G.E.T <http://www.regret.ie/>

[Bernt - Dieter Huismans](#), Letzte Revision Mai 2018 www.Huismans.click
Back to top: http://www.xerlebnishaft.de/lyme_vaccine.pdf

